Effects of aminosalicylates on thiopurine S-methyltransferase activity: An ex vivo study in patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 9, 2005, Pages 1105-1109

  Xin, H ^a,b   Fischer, C ^a   Schwab, M ^a   Klotz, U ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ALLOPURINOL; AMINOSALICYLIC ACID; AZATHIOPRINE; DIURETIC AGENT; MERCAPTOPURINE; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AMINOSALICYLIC ACIDS; DRUG INTERACTIONS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INHIBITORY CONCENTRATION 50; MALE; METHYLTRANSFERASES; MIDDLE AGED;

EID: 18444410760     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02460.x     Document Type: Article

References (23)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
2. Egan LJ, Sandborn WJ. Advances in the treatment of Crohn's disease. Gastroenterology 2004; 126: 1574-81.
3. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004; 126: 1582-92.
4. Egan LJ. Drug interactions in gastroenterology: mechanisms, consequences, and how to avoid. Clin Gastroenterol Hepatol 2004; 2: 725-30.
5. Ahmad T, Tamboli CP, Jewell D, Colombel J-F. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 2004; 126: 1533-49.
6. Evans WE. Pharmacogenetics of thiopurine S-methyl-transferase and thiopurine therapy. Ther Drug Monit 2004; 26: 186-91.
7. Dubinsky ML. Azathioprine, mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, safety. Clin Gastroenterol Hepatol 2004; 2: 731-43.
8. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407-17.
9. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
10. Schwab M, Schäffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-36.
11. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-9.
12. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. Balsalazide and azothioprine or mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 1999; 116: 1505-6.
13. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997; 62: 464-75.
14. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 656-64.
15. Dewit O, van Heuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16: 79-85.
16. Kröplin T, Weyer N, Gutsche S, Iven H. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguaninc as substrate. Eur J Clin Pharmacol 1998; 54: 265-71.
17. Kröplin T, Fischer C, Iven H. Inhibition of thiopurin S-methyltransferase activity by impurities in commercially available substrates: a factor for differing results of TPMT measurements. Eur J Clin Pharmacol 1999; 55: 285-91.
18. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62.
19. Sandborn WJ, Hanauer SB. Systematic review: The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003; 17: 29-42.
20. Laursen LS, Stokholm M, Bukhave K, Rask-Madsen J, Lauritzen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 1271-6.
21. Støa-Birketvedt G, Florholmen J. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. Aliment Pharmacol Ther 1999; 13: 357-61.
22. Shipkova M, Niedmann PD, Armstrong VW, Oellerich M, Wieland E. Determination of thiopurine methyltransferase in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. Clin Chem 2004; 50: 438-41.
23. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 1985; 10: 285-302.